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Abstract
A response to and comment on Pre-referral rectal artesunate in severe malaria: a flawed trial, by Karim F Hirji
and Zulfiqarali G Premji.
Letter
The most serious of the criticisms raised by Professors
Hirji and Premji in their assessment [1] of our study [2]
is that patients might have been enrolled by inadequately
trained village health workers and that patient safety and
welfare may therefore have been compromised. This is
speculative, and inaccurate. In the design of the study
and in its implementation, scrupulous care was taken to
ensure that all patients were carefully assessed, treated
and referred to facilities according to best practice in the
region and country, applying of course to both placebo
and artesunate recipients. It was a condition of the study
that sites should benefit from capacity development in
the conduct of clinical trials, strengthening of village
health worker involvement in the community, and public
participation and education at village level.
The design, execution and analysis reflected the two
principal outcomes of death or permanent disability which
were clearly defined. The study was planned to allow for
differences in practice and malaria endemicity at the var-
ious study sites, thus making it possible to reach more
general conclusions based on large numbers and variable
conditions of practice. Interim analyses were conducted by
an independent data monitoring committee, the outcomes
of which were not communicated during the course of the
study to the investigators. A data analysis plan agreed
before unblinding defined the exclusion of patients who
did not have malaria or had already received parenteral
anti-malarial just before randomisation. In the event, our
study produced significant and clinically meaningful
results.
There was exceptionally high level of follow up and
independent monitoring of the study, including continu-
ing peer review, which confirmed the scrupulous atten-
tion to detail and accuracy of the study at all its sites
and in all aspects. At study termination the trial was
inspected by international regulatory inspectors (hosted
by national regulatory authorities) to determine that the
rights, safety and welfare of human subjects had been
protected, verify procedures (including quality control
and training) and the validity of the data; each inspec-
tion concluded positively in every aspect.
I cannot comment on Hirji and Premji’s analysis of our
data using other statistical methods, based on data that
by their own submission appeared to be insufficient; nor
on what they arbitrarily refer to as ‘unlikely outcomes’.
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